Reservoir Neuroscience

Reservoir Neuroscience is an early-stage biotech targeting a novel mechanism in neurodegenerative diseases: blood-brain barrier (BBB) dysfunction. The company's core hypothesis is that repairing the BBB, a key regulator of brain homeostasis often compromised by neuroinflammation, could halt or reverse disease progression. Operating from the biotech hub of Cambridge, MA, the company is likely in a preclinical or discovery-stage phase, building its platform and pipeline. Its success hinges on validating this pioneering approach and translating it into effective clinical candidates for conditions like Alzheimer's and Parkinson's disease.

Proprietary small molecule discovery platform focused on identifying compounds that repair and heal the blood-brain barrier by targeting pathways involved in its integrity and function.

Competition is intense in neurodegenerative drug development, but direct competitors explicitly targeting BBB 'healing' are rare. The landscape includes large pharma and biotechs targeting neuroinflammation or specific proteinopathies (e.g., amyloid, tau). Reservoir's differentiation is its singular focus on the BBB as a primary therapeutic target, rather than a secondary consequence.